证券代码：300078 证券简称：思创医惠 公告编号：2025-055 思创医惠科技股份有限公司 关于公司为子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 4、注册资本：500 万元 5、法定代表人：刘念 一、担保情况概述 思创医惠科技股份有限公司（以下简称"公司"）于 2024 年 12 月 27 日、 2025 年 1 月 16 日分别召开第六届董事会第二次会议和 2025 年第一次临时股东 会，审议通过了《关于 2025 年度公司及子公司向金融机构申请综合授信及担保 额度预计的议案》，同意 2025 年度公司及子公司向金融机构申请综合授信额度 不超过人民币 5 亿元（含本数），并同意 2025 年度公司为合并报表范围内的子 公司提供总额不超过人民币 5 亿元（含本数）的担保，上述综合授信及担保额度 的有效期限为自 2025 年第一次临时股东会审议通过之日起 12 个月，上述预计额 度在有效期内可循环使用。具体内容详见公司于 2024 年 12 月 28 日在巨潮资讯 网（www.cninfo.com.cn）披露的《关于 2025 ...

Group 1 - The DRG/DIP concept declined by 3.30%, ranking among the top declines in the concept sector, with notable declines in companies such as Chuangying Huikang, ST Yilianzhong, and Jiahe Meikang [1][2] - The DRG/DIP concept experienced a net outflow of 4.92 billion yuan in main funds, with 19 stocks seeing net outflows, and 13 stocks with outflows exceeding 10 million yuan [2] - The stock with the highest net outflow was Donghua Software, with a net outflow of 1.26 billion yuan, followed by Chuangying Huikang, Weining Health, and Dian Diagnosis [2][3] Group 2 - The top stocks with net outflows in the DRG/DIP concept included Donghua Software (-3.97%), Chuangying Huikang (-6.76%), and Weining Health (-4.60%) [2][3] - Conversely, the stocks with net inflows included Huaping Co., Guoke Hengtai, and Wanda Information, with net inflows of 238.84 million yuan, 166.15 million yuan, and 121.00 million yuan respectively [2]

Group 1: Share Transfer and Control Changes - The share transfer agreement between Lu Nan and Cangnan Investment has been signed, pending regulatory approval and compliance confirmation from the Shenzhen Stock Exchange. After completion, Cangnan Finance Bureau will hold a total of 11.33% of the company's shares, becoming the actual controller [1][4] - The company is committed to timely disclosure of any necessary information as per regulatory requirements [1] Group 2: Future Development Strategy - The company focuses on "IoT-centric growth" as its core strategy for the next three years, aiming to enhance its IoT business and reduce its medical business operations [2][3] - The goal is to establish itself as a leading enterprise in the domestic RFID industry chain, with increased resource investment in IoT applications across various sectors [2] Group 3: Financial Performance - In 2024, the company's commercial intelligence business generated revenue of 500.80 million yuan, accounting for 72.50% of total revenue, while the smart medical business generated 170.31 million yuan, accounting for 24.66% [3] - The sale of medical technology assets was driven by significant revenue decline and continuous losses in the smart medical sector, allowing the company to focus on its core commercial intelligence business [3][4] Group 4: Strategic Partnerships - The strategic cooperation with Cangnan government aims to enhance long-term collaboration in the smart business sector, leveraging shared resources for mutual growth [3] Group 5: Recent Financial Transactions - The sale of medical technology assets generated 562 million yuan, with 304 million yuan recorded as other business income and 11.21 million yuan as asset disposal gains in Q1 2025 [4]

Group 1 - Aikolan's controlling shareholder Liu Yi terminated the share transfer agreement for 4 million shares, which represents 5% of the company's total share capital, with no change in control [1] - Wancheng Group announced a cash dividend of 4.00 yuan per 10 shares, totaling 71.9959 million yuan, with the record date on May 19, 2025 [1] - Wanda Film plans to invest in Lezi Tiancheng and engage in strategic cooperation, acquiring a total of 7% equity in the company [2] Group 2 - China Resources Double Crane's subsidiaries received approval for two drugs, indicating progress in their product pipeline [3] - Fosun Pharma's subsidiary's drug was included in the breakthrough therapy program, highlighting its innovative potential [4] - Zhongheng Group's subsidiary received approval for naloxone injection, enhancing its product offerings [5] Group 3 - Shenzhen Airport reported a passenger throughput of 5.3202 million in April, a year-on-year increase of 23.50% [8] - Hangzhou Bank successfully issued 5 billion yuan in technology innovation bonds, aimed at supporting tech innovation [10] - Jiuzhou Pharmaceutical received approval for a raw material drug used in treating severe depression, expanding its product range [12] Group 4 - Aihua Group reported a 25.38% decline in revenue for the first four months of the year, indicating potential challenges [27] - Changhua Group received a project designation notice from a well-known new energy vehicle company, with an expected total sales amount of approximately 108 million yuan [28] - Nanchao Food reported a slight revenue decrease of 0.98% in April, reflecting market conditions [30]

思创医惠科技股份有限公司（以下简称"公司"）董事会于近日收到公 司副总经理葛磊先生提交的书面辞职报告，葛磊先生因个人原因申请辞去公 司副总经理职务，辞职后继续在公司全资子公司医惠科技有限公司任职。根 据《中华人民共和国公司法》及《公司章程》等有关规定，葛磊先生的辞职 报告自送达董事会之日起生效。葛磊先生原定任期为 2024 年 12 月 6 日至 2027 年 12 月 5 日。 截至本公告披露日，葛磊先生未直接或间接持有公司股份，且不存在应 履行而未履行的承诺，辞职不会影响公司相关工作的正常进行。葛磊先生辞 职后，在原定任期及任期届满后六个月内仍将继续遵守《上市公司股东减持 股份管理暂行办法》《上市公司董事和高级管理人员所持本公司股份及其变 动管理规则》《深圳证券交易所上市公司自律监管指引第 18 号——股东及 董事、高级管理人员减持股份》等相关法律法规对任期届满前离任高级管理 人员股份转让的规定。 证券代码：300078 证券简称：思创医惠 公告编号：2025-054 思创医惠科技股份有限公司 关于公司副总经理辞职的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述 ...

5月9日，衡财保·炜衡金融315团队向投资快报记者表示，近期，部分投资者起诉思创医惠证券虚假陈述 索赔案件二审宣判，投资者终审胜诉。该团队目前正在联系思创医惠沟通调解事宜。此外，思创医惠案 件诉讼时效将于今年10月到期，如还想挽回损失的股民需抓紧时间维权。 2024年1月9日，思创医惠科技股份有限公司（简称"思创医惠"，证券代码300078）发布公告称，公司于 2024年1月8日收到中国证监会浙江监管局下发的《行政处罚决定书》（【2023】49号）及《市场禁入决 定书》（【2023】5号）。公告显示，思创医惠存在可转债欺诈发行行为，并且2019-2020年年度报告未 能如实披露财务数据，致使这两年年报存在虚假记载。 调查显示，思创医惠通过全资子公司医惠科技，分别与杭州闻然、上海洗凡、深圳雨淋开展虚假业务交 易。2019 年，思创医惠通过上述虚假业务，累计虚增营业收入 34,929,355.97 元，虚增利润 33,021,672.43 元，虚增利润数额占公司当期利润总额的 20.03％，致使《2019 年年度报告》财务数据披 露严重失实。 2020 年，医惠科技虚假业务规模进一步扩大，不仅持续与杭州闻然、上海 ...

Group 1 - The core viewpoint of the news is that a comprehensive financial policy package has been introduced to support the stability of the market and expectations, particularly benefiting the elderly care sector [1][3] - The People's Bank of China has established a 500 billion yuan service consumption and elderly care relending tool to enhance financial support for key areas such as elderly care and service consumption [3] - The elderly care industry in China is projected to reach a scale of 9 trillion yuan in 2022, with expectations to exceed 12 trillion yuan by 2025, indicating a significant growth phase ahead [4][5] Group 2 - The elderly care concept stocks have shown strong performance, with multiple stocks such as Jinming Precision Machinery and Xinhua Jin experiencing significant price increases, some reaching the daily limit [2] - The new policy tool is an expansion and upgrade of the previous inclusive elderly care relending policy, which had a smaller quota of 40 billion yuan and was initially piloted [3] - The silver economy is expected to grow substantially, with projections indicating it could reach 30 trillion yuan by 2035, accounting for 10% of GDP, driven by various sectors including elderly services and health care [4]

Core Insights - The company reported a total revenue of 691 million yuan for 2024, a decrease of 315 million yuan compared to the previous year, representing a year-on-year decline of 31.33% [1] - The net profit attributable to shareholders was -502 million yuan, ranking 118 among peers [1] - The operating cash flow showed a net outflow of 35.68 million yuan, a decrease of 47.47 million yuan year-on-year, reflecting a decline of 402.72% [1] Financial Performance - The latest debt-to-asset ratio stands at 73.11%, ranking 120 among peers [3] - The gross profit margin is reported at 12.14%, ranking 118 among peers [3] - The return on equity (ROE) is -86.50%, ranking 126 among peers [3] Earnings and Ratios - The diluted earnings per share is -0.53 yuan, ranking 101 among peers [4] - The total asset turnover ratio is 0.29 times, a decrease of 0.03 times year-on-year, reflecting a decline of 10.58% [4] - The inventory turnover ratio is 3.08 times, ranking 75 among peers [4] Shareholder Information - The number of shareholders is 48,700, with the top ten shareholders holding 291 million shares, accounting for 25.85% of the total share capital [4] - The largest shareholder is 苍南县思加物联智能合伙企业(有限合伙) with a holding of 5.68% [4] Research and Development - The total R&D investment is 102 million yuan, ranking 5th in the last five years, with a decrease of 53.56 million yuan year-on-year, representing a decline of 34.49% [4] - The latest R&D investment ratio is 14.73%, ranking 4th in the last five years, with a decrease of 0.71 percentage points year-on-year [4]

Group 1 - The core viewpoint of the news is that Sichuang Medical has reported significant losses in 2024 but is actively transforming its business model to improve its financial situation and operational performance [1][2] - In 2024, Sichuang Medical's operating revenue was 691 million yuan, with a net loss attributable to shareholders of 502 million yuan, a reduction in losses by 42.64% year-on-year [1] - The company reported a net profit loss of 442 million yuan after excluding non-recurring items, which is a 50.88% reduction in losses compared to the previous year [1] Group 2 - Sichuang Medical has officially initiated the complete divestiture of its smart medical business to optimize its business structure and focus on its core operations [2] - The company aims to enhance its financial status and performance metrics through this strategic adjustment, which is expected to improve asset quality and profitability [2] - The focus will shift to the Internet of Things (IoT) sector, leveraging its strong technical foundation and practical experience in commercial intelligence [2] Group 3 - Sichuang Medical's products are exported to over 70 countries and regions, showcasing its strong international competitiveness and positive global market reputation [3] - The company has established long-term stable partnerships with over 300 global clients and agents, promoting the development of the commercial intelligence sector [3] - The establishment of the Cangnan IoT application production base marks a new phase in the company's strategic transformation and industrial upgrade [3] Group 4 - The entry of Cangnan State-owned Assets has provided new opportunities for Sichuang Medical, integrating the company's strategy with local industrial development [4] - A strategic cooperation agreement has been signed between Cangnan County Government and Sichuang Medical, focusing on four core areas: industrial integration, talent development, financial support, and capital cooperation [4] - This partnership is expected to ensure the stable operation of Sichuang Medical and promote sustainable development in the commercial intelligence market [4]

1、公司以前年度中保留意见涉及事项仍然无法判断相关交易的商业实质及 其真实性、公允性、合理性，以及对公司 2024 年度财务报表可能产生影响，因 此，天健会计师事务所（特殊普通合伙）对公司 2024 年度审计报告继续出具了 保留意见审计报告，我们尊重其独立判断。 2、公司监事会将认真履行监督职责，督促公司董事会和管理层落实其制定 的整改方案，尽快消除审计报告中保留意见涉及事项的影响，切实维护公司及全 体股东的合法权益，保证公司可持续发展。 特此说明。 证券代码：300078 证券简称：思创医惠 公告编号：2025-042 思创医惠科技股份有限公司 监事会对董事会关于 2024 年度保留意见审计报告涉及事项 的专项说明 思创医惠科技股份有限公司（以下简称"公司"）聘请的天健会计师事务所 （特殊普通合伙）对公司 2024 年度财务报告出具了保留意见的审计报告。 根据《深圳证券交易所创业板股票上市规则》《公开发行证券的公司信息披 露编报规则第 14 号——非标准审计意见及其涉及事项的处理》等相关规定，公 司监事会对董事会作出的《思创医惠科技股份有限公司董事会关于 2024 年度保 留意见审计报告涉及事项的专项说明》 ...